Liquid biopsy, in the form of circulating tumour DNA (ctDNA), has potential to revolutionise the personalised management of colorectal cancer (CRC). For patients with early-stage disease, emerging clinical applications include minimal residual disease (MRD) assessment post-surgery, monitoring of adjuvant chemotherapy efficacy, and early detection of recurrence during surveillance. The presentation will provide an overview of the current evidence supporting the use of ctDNA in CRC, the studies underway to address some of the outstanding questions, and the barriers to widespread clinical uptake.